This study laid the groundwork for a Phase 0 clinical trial (NCT03020017) which assessed the safety and efficacy of gold NP-based SNAs conjugated with siRNA specific to Bcl2L12 in patients with recurrent GBM or gliosarcoma [432]. The gene discussed is BCL2L12; the disease is gliosarcoma.